BRPI0923373B8 - composições farmacêuticas compreendendo uma combinação de insulina com derivados de triazina, e uso da dita combinação - Google Patents

composições farmacêuticas compreendendo uma combinação de insulina com derivados de triazina, e uso da dita combinação

Info

Publication number
BRPI0923373B8
BRPI0923373B8 BRPI0923373A BRPI0923373A BRPI0923373B8 BR PI0923373 B8 BRPI0923373 B8 BR PI0923373B8 BR PI0923373 A BRPI0923373 A BR PI0923373A BR PI0923373 A BRPI0923373 A BR PI0923373A BR PI0923373 B8 BRPI0923373 B8 BR PI0923373B8
Authority
BR
Brazil
Prior art keywords
insulin
combination
compound
formula
triazine derivatives
Prior art date
Application number
BRPI0923373A
Other languages
English (en)
Inventor
Audet Annick
Cravo Daniel
Mesangeau Diddier
Original Assignee
Merck Patent Gmbh
Poxel S A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Poxel S A S filed Critical Merck Patent Gmbh
Publication of BRPI0923373A2 publication Critical patent/BRPI0923373A2/pt
Publication of BRPI0923373B1 publication Critical patent/BRPI0923373B1/pt
Publication of BRPI0923373B8 publication Critical patent/BRPI0923373B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

combinação de insulina com derivados de triazina e seu uso para tratar diabetes. a presente invenção refere-se a uma composição para uso como um medicamento compreendendo insulina em combinação com pelo menos um composto de fórmula (l) em que os radicais r1 to r6 têm o significados de acordo com a reivindicação 1, e/ou sais fisiologicamente aceitáveis dos mesmos. outro objetivo da invenção diz respeito a uma composição farmacêutica compreendendo como ingredientes ativos quantidades eficazes de insulina e pelo menos um composto de formula (l), junto com adjuvantes farmaceuticamente toleráveis, para o tratamento e/ou monitoramento profilático ou terapêutico de condições fisiológicas e/ou patológicas que estão associadas com resistência à insulina. a invenção também refere-se a uma embalagem farmacêutica compreendendo insulina em uma primeira unidade de dosagem e pelo menos um composto de fórmula (l) em uma segunda unidade de dosagem.
BRPI0923373A 2008-12-12 2009-11-13 composições farmacêuticas compreendendo uma combinação de insulina com derivados de triazina, e uso da dita combinação BRPI0923373B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08021617 2008-12-12
EP08021617.9 2008-12-12
PCT/EP2009/008099 WO2010066326A1 (en) 2008-12-12 2009-11-13 Combination of insulin with triazine derivatives and its use for treating diabetes

Publications (3)

Publication Number Publication Date
BRPI0923373A2 BRPI0923373A2 (pt) 2015-07-21
BRPI0923373B1 BRPI0923373B1 (pt) 2020-02-11
BRPI0923373B8 true BRPI0923373B8 (pt) 2021-05-25

Family

ID=41566311

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0923373A BRPI0923373B8 (pt) 2008-12-12 2009-11-13 composições farmacêuticas compreendendo uma combinação de insulina com derivados de triazina, e uso da dita combinação

Country Status (23)

Country Link
US (2) US8592370B2 (pt)
EP (1) EP2355829B1 (pt)
JP (1) JP5667985B2 (pt)
KR (1) KR101623819B1 (pt)
CN (1) CN102245185A (pt)
AR (1) AR074555A1 (pt)
AU (1) AU2009326604B2 (pt)
BR (1) BRPI0923373B8 (pt)
CA (1) CA2746479C (pt)
CY (1) CY1115973T1 (pt)
DK (1) DK2355829T3 (pt)
EA (1) EA021395B1 (pt)
ES (1) ES2530223T3 (pt)
HR (1) HRP20150064T1 (pt)
IL (1) IL213421A (pt)
MX (1) MX2011006073A (pt)
PL (1) PL2355829T3 (pt)
PT (1) PT2355829E (pt)
SG (1) SG171986A1 (pt)
SI (1) SI2355829T1 (pt)
SM (1) SMT201500032B (pt)
WO (1) WO2010066326A1 (pt)
ZA (1) ZA201105094B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011154496A1 (en) * 2010-06-09 2011-12-15 Poxel Treatment of type 1 diabetes
TWI436768B (zh) * 2010-06-09 2014-05-11 Poxel 第２型糖尿病之治療
MX359171B (es) * 2011-12-12 2018-09-18 Melior Pharmaceuticals I Inc Tratamiento para diabetes tipo i y tipo ii.
WO2019069230A1 (en) 2017-10-02 2019-04-11 Poxel METHODS OF TREATING CARDIAC INSUFFICIENCY WITH PRESERVED EJECTION FRACTION
AU2019282727A1 (en) 2018-06-06 2020-11-26 Metavant Sciences Gmbh Methods of treating subjects having diabetes with chronic kidney disease
MX2020013567A (es) 2018-06-14 2021-05-27 Poxel Tableta recubierta con pelicula que comprende un derivado de triazina para su uso en el tratamiento de la diabetes.
WO2021117861A1 (ja) * 2019-12-13 2021-06-17 大日本住友製薬株式会社 製造性及び溶出性に優れた小型錠剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3172814A (en) * 1962-04-06 1965-03-09 Jr Edgar A Ferguson Oral blood sugar lowering compositions
FR2738741B1 (fr) * 1995-09-19 1997-12-05 Oreal Composition pour la teinture des fibres keratiniques, contenant un antagoniste de substance p
FR2804113B1 (fr) * 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
EP1355651A2 (en) * 2001-02-02 2003-10-29 Pfizer Limited Treatment of diabetes mellitus using vardenafil
DE10301788B4 (de) 2003-01-20 2005-08-25 Aventis Pharma Deutschland Gmbh Pharmazeutische Verwendung von Pyrimido[5,4-e][1,2,4]triazin-5,7-dionen
FR2896159B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.

Also Published As

Publication number Publication date
EP2355829A1 (en) 2011-08-17
SG171986A1 (en) 2011-07-28
BRPI0923373B1 (pt) 2020-02-11
SMT201500032B (it) 2015-05-05
BRPI0923373A2 (pt) 2015-07-21
AR074555A1 (es) 2011-01-26
EA201100916A1 (ru) 2012-01-30
US20110306543A1 (en) 2011-12-15
US8592370B2 (en) 2013-11-26
CY1115973T1 (el) 2017-01-25
US8980828B2 (en) 2015-03-17
CA2746479A1 (en) 2010-06-17
US20130310312A1 (en) 2013-11-21
JP5667985B2 (ja) 2015-02-12
KR101623819B1 (ko) 2016-05-24
SI2355829T1 (sl) 2015-03-31
PL2355829T3 (pl) 2015-04-30
KR20110106354A (ko) 2011-09-28
EP2355829B1 (en) 2014-12-31
MX2011006073A (es) 2011-06-24
DK2355829T3 (en) 2015-02-16
CA2746479C (en) 2016-11-08
IL213421A0 (en) 2011-07-31
HRP20150064T1 (hr) 2015-02-27
JP2012511521A (ja) 2012-05-24
IL213421A (en) 2017-02-28
WO2010066326A1 (en) 2010-06-17
AU2009326604B2 (en) 2014-07-31
EA021395B1 (ru) 2015-06-30
ES2530223T3 (es) 2015-02-27
AU2009326604A1 (en) 2011-07-28
CN102245185A (zh) 2011-11-16
PT2355829E (pt) 2015-02-20
ZA201105094B (en) 2012-03-28

Similar Documents

Publication Publication Date Title
BRPI0923373B8 (pt) composições farmacêuticas compreendendo uma combinação de insulina com derivados de triazina, e uso da dita combinação
BR112014012815A2 (pt) derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015001419A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BR112013016021A2 (pt) métodos e composições adequadas para gerenciar glicemia em animais
BRPI1015996B8 (pt) composição oftálmica de múltiplas doses contendo complexos de borato-poliol.
CY1114215T1 (el) Φαρμακευτικες συνθεσεις διαλυματος για υπο πιεση εισπνευστηρες μετρουμενης δοσης
BR112015000136A2 (pt) fibra alimentar para uso no tratamento de um efeito colateral gastrintestinal de uma nutrição ou medicamento
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
BR112012006010A2 (pt) composto de glicina
DE602006017728D1 (de) Krebsbehandlung mittels fts und 2-deoxyglucose
MX2009011900A (es) Curacion de herida diabetica.
BR112022009805A2 (pt) Derivados de piridopirimidinona como antagonistas de ahr
BR112014006223A2 (pt) 6-substituídas-3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas como tirosina quinase c-met
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112012022074A2 (pt) composição compreendendo como ingredientes ativos l-carnitina em combinação com hidroxiquinurenina-o-beta-dl-glicosídeo, para a prevenção e/ou tratamento de patologias dos olhos devido à radiação ultravioleta
BR112012020185A2 (pt) uso de preparações de heparina oral para tratar doenças e afecções do trato urinário.
DK1482919T3 (da) Farmaceutisk sammensætning til blodsukkerkontrol hos patienter med type 2 diabetes
BR112014002885A2 (pt) uso de composto orgânico para o tratamento da síndrome de noonan
EA201070557A1 (ru) Способы и композиции для замедления набора веса, связанного с применением атипичных антипсихотических препаратов
BR112012028652A2 (pt) hidroxialquilbenzilpirazois e seu uso
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: POXEL S.A.S. (FR)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/02/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/11/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF